AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10159752 — intervention group
Group type: COMPARATOR
Intervention: Experienced attending physician as primary operator
Number of subjects: 50
Study 2283650 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg once daily)
Number of subjects: 0
Study 2283650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 378316 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/0 Dexon suture subcuticularly
Number of subjects: 0
Study 378316 — intervention group
Group type: COMPARATOR
Intervention: Other suture methods (not specified)
Number of subjects: 0
Study 31856601 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges and barriers identified through a three-round modified Delphi survey with international trials researchers.
Number of subjects: 0
Study 29541862 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate nasal spray (0.1 mg/ml, 10 μg/spray) once daily for 10 days
Number of subjects: 110
Study 29541862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 29541862 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate nasal spray
Number of subjects: 110
Study 29757889 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-signal T-cell activation (T-cell receptor activation, CD137/4-1BB stimulation, interleukin-2)
Number of subjects: 0
Study 29757889 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-signal T-cell activation
Number of subjects: 0
Study 27358142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose oral solution, 15 ml once a day, maintenance dose of 515 ml/time as needed, treatment lasted for six weeks.
Number of subjects: 211
Study 27358142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose oral solution
Number of subjects: 211
Study 27358142 — intervention group
Group type: COMPARATOR
Intervention: Control group (blank controls)
Number of subjects: 211
Study 24768330 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for residual disease (Arm A)
Number of subjects: 41
Study 24768330 — intervention group
Group type: COMPARATOR
Intervention: Imatinib mesylate (IM) treatment alone (Arm B)
Number of subjects: 41
Study 21866055 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height (r = 0.324 at 6 months)
Number of subjects: 412
Study 21866055 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height (r = 0.335 at 12 months)
Number of subjects: 412
Study 21866055 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height
Number of subjects: 412
Study 20558081 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of managing gastric residual volume (returning vs discarding)
Number of subjects: 0
Study 17959975 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air-warming
Number of subjects: 30
Study 17959975 — intervention group
Group type: COMPARATOR
Intervention: Control (identical cover with forced air-warming unit switched off)
Number of subjects: 30
Study 17959975 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 15805381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucinactant
Number of subjects: 252
Study 15805381 — intervention group
Group type: COMPARATOR
Intervention: Poractant alfa
Number of subjects: 252
Study 12356634 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial flutter termination
Number of subjects: 35
Study 12356634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at cycle lengths of 750 to 250 ms
Number of subjects: 35
Study 12356634 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol administration
Number of subjects: 35
Study 12356634 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium administration
Number of subjects: 35
Study 12356634 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpacing pause
Number of subjects: 35
Study 12356634 — intervention group
Group type: COMPARATOR
Intervention: Paroxysmal AFL group (control)
Number of subjects: 35
Study 10096462 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-back hormone replacement therapy (HRT)
Number of subjects: 0
Study 10096462 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose progestogen
Number of subjects: 0
Study 10096462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose progestogen plus cyclical etidronate
Number of subjects: 0
Study 10096462 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and low-dose HRT add-back
Number of subjects: 0
Study 10096462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose and standard-dose add-back HRT
Number of subjects: 0
Study 7762716 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 3348
Study 7762716 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus interactive group discussion
Number of subjects: 3348
Study 7762716 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3348
Study 1980611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic medication
Number of subjects: 10
Study 7000239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna (twice for 25 minutes at 85 degrees C)
Number of subjects: 8
Study 7000239 — intervention group
Group type: COMPARATOR
Intervention: Room temperature (control)
Number of subjects: 8
Study 29973367 — intervention group
Group type: EXPERIMENTAL
Intervention: Known or newly diagnosed diabetes
Number of subjects: 1192
Study 29973367 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose level ≥200 mg/dL in participants with known diabetes
Number of subjects: 1192
Study 29973367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmological examination for diabetic retinopathy (DR)
Number of subjects: 1192
Study 29973367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of diabetic retinopathy (DR) and/or maculopathy
Number of subjects: 1192
Study 29973367 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted and sex-adjusted prevalence of diabetes
Number of subjects: 1192
Study 30098071 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily, prolonged-release tacrolimus (PR-T)
Number of subjects: 100
Study 30098071 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily, immediate-release tacrolimus (IR-T)
Number of subjects: 100
Study 30098071 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PR-T and IR-T
Number of subjects: 100
Study 27559727 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP‐α plasma level in women with preeclampsia (PE)
Number of subjects: 124
Study 27559727 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP‐α plasma level in women without severe features of PE
Number of subjects: 124
Study 27559727 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP staining in placentas of women with PE
Number of subjects: 124
Study 27559727 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP staining in placentas of women without severe features of PE
Number of subjects: 124
Study 24631433 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch or fascial sling surgery
Number of subjects: 491
Study 22240272 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone-ER
Number of subjects: 181
Study 22240272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 22240272 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 181
Study 19632524 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 500
Study 19632524 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 500
Study 17502757 — intervention group
Group type: EXPERIMENTAL
Intervention: EnSite NavX-guided ablation (group II, n=38)
Number of subjects: 73
Study 17502757 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided ablation (group I, n=35)
Number of subjects: 73
Study 15175957 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative two drug chemotherapy for stage I in intermediate risk or anaplasia reduced from 3 courses to 1 course
Number of subjects: 637
Study 15175957 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 637
Study 15175957 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 637
Study 15175957 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-chemotherapy blastemal predominant subtype
Number of subjects: 637
Study 15175957 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal anaplasia
Number of subjects: 637
Study 11597384 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care protocol intervention (tooth brushing, 0.2% chlorhexidine mouth rinse, 0.9% saline rinse)
Number of subjects: 42
Study 11597384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral care protocol)
Number of subjects: 42
Study 9589759 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment (ACT)
Number of subjects: 223
Study 9589759 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 223
Study 7818835 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 0
Study 2977328 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 90
Study 2977328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no behavioral intervention)
Number of subjects: 90
Study 29127458 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 (IV; 0.2-120 mg)
Number of subjects: 72
Study 29127458 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 (SC; 40-120 mg)
Number of subjects: 72
Study 29127458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 29127458 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 (IV; doses ≥ 20 mg)
Number of subjects: 72
Study 29127458 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 (SC; 120 mg)
Number of subjects: 72
Study 26443242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 4133
Study 26443242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study 24746358 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin
Number of subjects: 221
Study 24746358 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 221
Study 24746358 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 221
Study 22688136 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 24
Study 20420756 — intervention group
Group type: EXPERIMENTAL
Intervention: Convenience drink supplemented with n‐3 fatty acids (200 mg EPA and 300 mg DHA)
Number of subjects: 50
Study 20420756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.1 g linoleic acid from maize oil)
Number of subjects: 50
Study 17705160 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Neuromuscular Electrical Stimulation
Number of subjects: 74
Study 17705160 — intervention group
Group type: COMPARATOR
Intervention: Placebo Neuromuscular Electrical Stimulation
Number of subjects: 74
Study 15970792 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH dose of 150 U/day (Group I, Ser/Ser)
Number of subjects: 93
Study 15970792 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH dose of 225 U/day (Group II, Ser/Ser)
Number of subjects: 93
Study 15970792 — intervention group
Group type: COMPARATOR
Intervention: FSH dose of 150 U/day (Group III, Asn/Asn)
Number of subjects: 93
Study 15600135 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning bright light
Number of subjects: 0
Study 15600135 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening bright light
Number of subjects: 0
Study 10589812 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video (group V)
Number of subjects: 26
Study 10589812 — intervention group
Group type: COMPARATOR
Intervention: Instructional leaflet (group L)
Number of subjects: 26
Study 8909623 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Dates Project program including a theater production, a 10-session curriculum, and a poster contest.
Number of subjects: 1967
Study 8909623 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Dates Project program
Number of subjects: 1967
Study 8909623 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1967
Study 8101772 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg BID)
Number of subjects: 42
Study 8101772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3565301 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted MHD patients predialysis
Number of subjects: 24
Study 3565301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasted MHD patients
Number of subjects: 24
Study 3565301 — intervention group
Group type: EXPERIMENTAL
Intervention: All MHD patients predialysis and postdialysis
Number of subjects: 24
Study 3565301 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 24
Study 28844717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 48
Study 28844717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28959471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 26307539 — intervention group
Group type: EXPERIMENTAL
Intervention: FamHFcare intervention
Number of subjects: 20
Study 23047595 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose telmisartan (80 mg/day) combined with trichlormethiazide (1 mg/day)
Number of subjects: 40
Study 23047595 — intervention group
Group type: COMPARATOR
Intervention: Triple combination of telmisartan (40 mg/day), trichlormethiazide (1 mg/day), and amlodipine (5 mg/day)
Number of subjects: 40
Study 22051143 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive (swallowing) exercise program (PREP)
Number of subjects: 0
Study 22051143 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 19641331 — intervention group
Group type: EXPERIMENTAL
Intervention: First-ever stroke patients
Number of subjects: 2051
Study 16484911 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet supplemented with eicosapentaenoic acid (EPA) and gamma-linolenic acid (GLA) for 14 days
Number of subjects: 100
Study 16484911 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 100
Study 12628899 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction therapy with nature sights and sounds (nature scene murals and nature sounds tape)
Number of subjects: 80
Study 12628899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nature sights or sounds)
Number of subjects: 80
Study 10669333 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent antiretroviral therapy (protease inhibitor‐containing)
Number of subjects: 11
Study 10669333 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics (virus load and CD4+ T cell count)
Number of subjects: 11
Study 8951263 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based cereal diet (n = 60)
Number of subjects: 116
Study 8951263 — intervention group
Group type: COMPARATOR
Intervention: Milk-free cereal diet (n = 56)
Number of subjects: 116
Study 8951263 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 2023702 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prochlorperazine infusion and dexamethasone (HDPD)
Number of subjects: 20
Study 2023702 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide and dexamethasone (HDMD)
Number of subjects: 20
Study 7067184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release metoprolol (200 mg durule)
Number of subjects: 10
Study 7067184 — intervention group
Group type: COMPARATOR
Intervention: Conventional metoprolol (100 mg twice daily)
Number of subjects: 10
Study 31810462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined functional resistance and endurance exercises 60 min, 3 times per week for 12 weeks
Number of subjects: 64
Study 28498078 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-administration of Kinetic Oscillatory Stimulation (KOS) catheter
Number of subjects: 29
Study 28498078 — intervention group
Group type: COMPARATOR
Intervention: Insertion of KOS catheter by physician with helmet fixation
Number of subjects: 29
Study 28498078 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-administration of KOS catheter
Number of subjects: 29
Study 28498078 — intervention group
Group type: EXPERIMENTAL
Intervention: Total study population (n = 26)
Number of subjects: 29
Study 25296740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo-chamber therapy at -67 °C
Number of subjects: 0
Study 25296740 — intervention group
Group type: COMPARATOR
Intervention: Sham cryo-chamber therapy at -5 °C
Number of subjects: 0
Study 23819221 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (1 Hz/50 Hz) for 30 min once daily for 14 days
Number of subjects: 90
Study 23819221 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/kg for first 3 days, 0.2 mg/kg for 7 days, 0.1 mg/kg afterwards)
Number of subjects: 90
Study 23819221 — intervention group
Group type: COMPARATOR
Intervention: Routine medication (mild hypothermia, dehydration medicines, hormonal therapy, vascular dilation, cerebral nutrition, anti-inflammation)
Number of subjects: 90
Study 21764840 — intervention group
Group type: COMPARATOR
Intervention: Control diet containing 70% corn and 0% SH
Number of subjects: 16
Study 21764840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 15% SH
Number of subjects: 16
Study 21764840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 30% SH
Number of subjects: 16
Study 21764840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 45% SH
Number of subjects: 16
Study 21764840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with SH
Number of subjects: 16
Study 19167143 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to research participation rated by participants
Number of subjects: 285
Study 19167143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and gender by age interactions
Number of subjects: 285
Study 19167143 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline barriers
Number of subjects: 285
Study 19167143 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate social support, unstable job, and the use of alcohol and drugs
Number of subjects: 285
Study 16622139 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 534
Study 16622139 — intervention group
Group type: COMPARATOR
Intervention: Resin composite
Number of subjects: 534
Study 15636250 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue staining during surgery
Number of subjects: 0
Study 15636250 — intervention group
Group type: COMPARATOR
Intervention: No trypan blue staining during surgery
Number of subjects: 0
Study 11327549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 41
Study 11327549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) treatment
Number of subjects: 41
Study 9121502 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-GM1 antibodies
Number of subjects: 124
Study 9121502 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-GQ1b antibodies
Number of subjects: 124
Study 9121502 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anti-GM1 antibodies
Number of subjects: 124
Study 9121502 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anti-GQ1b antibodies
Number of subjects: 124
Study 8002061 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dose of hydrocortisone (20 mg/m2 daily)
Number of subjects: 13
Study 8002061 — intervention group
Group type: COMPARATOR
Intervention: Night dose of hydrocortisone (20 mg/m2 daily)
Number of subjects: 13
Study 3042841 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone HCl 2.0 mg/kg IV bolus
Number of subjects: 8
Study 3042841 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone HCl 0.1 mg/kg IV bolus
Number of subjects: 8
Study 3042841 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone HCl 5 micrograms/kg IV bolus
Number of subjects: 8
Study 3042841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30385649 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg nicotine/g tobacco)
Number of subjects: 0
Study 30385649 — intervention group
Group type: COMPARATOR
Intervention: Usual Brand (UB) cigarettes
Number of subjects: 0
Study 27782128 — intervention group
Group type: EXPERIMENTAL
Intervention: FEP group
Number of subjects: 272
Study 27782128 — intervention group
Group type: COMPARATOR
Intervention: FEP, MDD, and PTSD groups
Number of subjects: 272
Study 25402372 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin 1700 mg/d plus vildagliptin 100 mg/d
Number of subjects: 64
Study 25402372 — intervention group
Group type: COMPARATOR
Intervention: metformin 1700 mg/d
Number of subjects: 64
Study 23358831 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical biochip technology for MMP 7 analysis
Number of subjects: 30
Study 23358831 — intervention group
Group type: COMPARATOR
Intervention: Standard ELISA technique for MMP 7 analysis
Number of subjects: 30
Study 21600723 — intervention group
Group type: EXPERIMENTAL
Intervention: High patient-centered communication (PCC) vignettes
Number of subjects: 248
Study 21600723 — intervention group
Group type: COMPARATOR
Intervention: Low patient-centered communication (PCC) vignettes
Number of subjects: 248
Study 18462835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 0
Study 18462835 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 16527024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured tracheostomy site
Number of subjects: 75
Study 16527024 — intervention group
Group type: COMPARATOR
Intervention: Nonsutured tracheostomy site
Number of subjects: 75
Study 12930192 — intervention group
Group type: EXPERIMENTAL
Intervention: A-CAL
Number of subjects: 35
Study 12930192 — intervention group
Group type: EXPERIMENTAL
Intervention: A-WT
Number of subjects: 35
Study 12930192 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 10987449 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions
Number of subjects: 2879